Sullivan & Cromwell Reps Amgen In $1B BioVex Deal

Law360, New York (January 25, 2011, 2:11 PM EST) -- Amgen Inc. has agreed to pay up to $1 billion to acquire Woburn, Mass.-based biotechnology company BioVex Group Inc., the maker of an experimental cancer vaccine.

In an announcement Monday, Thousand Oaks, Calif.-based Amgen said that it will pay $425 million when the deal closes following regulatory approval, expected in the first quarter of the year.

In addition, Amgen will make up to $575 million in payments upon the achievement of certain regulatory and sales milestones, the company said.

BioVex is developing a vaccine called OncoVEX,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.